TheEdgeResearch
Home / Stocks / VKTX

Viking Therapeutics, Inc. (VKTX)

NASDAQ Healthcare Biotechnology
$24.77 ▼ -4.14%
Market Cap
$3.16B
Sector
Healthcare
Industry
Biotechnology
Beta
0.65
52-Wk Range
23.82-43.1
CEO
Brian Lian
Country
US
Currency
USD

Viking Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $24.77, down 4.14% on the session, giving a market capitalisation of $3.16B. On trailing twelve-month figures it carries a trailing P/E of -4.59, a net margin of 0.0%. Its beta of 0.65 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-4.59
Price / Sales
0.00
Price / Book
4.97
EV / EBITDA
-4.36
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.43
Current ratio
7.27
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
74
IPO date
2015-04-28
Headquarters
San Diego, CA, US
About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Comparable companies

Viking Therapeutics, Inc. is most often compared with the following Healthcare names:

KLRAMBXMDGLNAMSSEPNVTVT
More research on VKTX
VKTX technical analysis VKTX TheEdge Score Compare against peers
Open full interactive analysis & DCF →